AOD-9604 + MOTS-C (5mg + 10mg)
A dual metabolic action stack: AOD-9604 (GH fragment 176-191) directly targets lipolysis via beta-3 adrenergic receptors, while MOTS-C (a mitochondrial peptide) optimizes metabolic homeostasis through AMPK activation and improved insulin sensitivity. Ideal for body recomposition in metabolically dysfunctional phenotypes.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
**AOD-9604** activates lipolysis via beta-3 adrenergic receptors, increasing fatty acid release without raising IGF-1. **MOTS-C** activates AMPK (AMP-activated protein kinase), improves mitochondrial beta-oxidation, increases GLUT4 transport, and reduces de novo lipogenesis. Together, the two peptides act on **complementary metabolic pathways**: AOD on adipocytes (lipolysis) and MOTS-C on mitochondria (metabolic regulation).
Quick Start
- AOD-9604: 300 mcg SC, 1x/day (fasted, in the morning)
- MOTS-C: 5 mg SC, 3x/week (on workout days)
- Cycle: 8–12 weeks
- Storage: Refrigerator 2–8°C after reconstitution
Dosing Table — AOD-9604 + MOTS-C Stack
Route: Subcutaneous (SC) | Frequency: See per peptide
| Week | Dose | Units (per injection) |
|---|---|---|
| 1–2 | 250mcg AOD daily / 5mg MOTS-C 3x/wk | 2 × 100 Units (1.00 mL) |
| 3–8 | 300mcg AOD daily / 5mg MOTS-C 3x/wk | 2 × 100 Units (1.00 mL) |
| 9–12 | 300mcg AOD daily / 5mg MOTS-C 3x/wk | 2 × 100 Units (1.00 mL) |
AOD-9604: daily in the morning, fasted (30 minutes before food). MOTS-C: 3x/week in the morning, in studies typically on days involving physical activity.
Related compounds
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
AOD-9604 (5 mg)
MOTS-C (10 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- AOD-9604 (5 mg): Add 2.0 mL BAC water → 2.5 mg/mL.
- MOTS-C (10 mg): Add 2.0 mL BAC water → 5 mg/mL.
- Gently swirl — do not shake.
Protocol Overview
- AOD-9604 is a modified fragment (176-191) of HGH, specialized for lipolysis without anabolic/hyperglycemic effects.
- MOTS-C (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino acid mitochondrial peptide that regulates glucose, lipid metabolism, and insulin sensitivity.
- The combination: direct lipolysis (AOD) + metabolic optimization (MOTS-C) = a holistic approach to fat loss.
Dosing Protocol
- AOD-9604: 250–300 mcg SC, 1x/day, fasted in the morning.
- MOTS-C: 5 mg SC, 3x/week (Mon-Wed-Fri or on workout days).
- Cycle: 8–12 weeks → 4-week break.
- MOTS-C is administered in the morning for optimal metabolic action.
- Break between cycles: 4-week break for metabolic reset.
Washout & Cycle Restart
When can I restart?
4-week break for metabolic reset.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C (12–24 months).
- Reconstituted: 2–8 °C, use within 4 weeks.
Important Notes
- MOTS-C activates AMPK — avoid concurrent administration of exogenous insulin.
- AOD-9604 is administered in a fasted state — insulin inhibits lipolysis.
- Ideal for metabolic syndrome / insulin resistance.
- Monitoring of fasting glucose and HbA1c is recommended.
Potential Benefits & Side Effects
Potential Benefits:
- Targeted lipolysis (AOD-9604)
- Improved insulin sensitivity (MOTS-C/AMPK)
- Enhanced mitochondrial function
- Reduction of visceral fat
- Improved exercise endurance
- Does not affect IGF-1, GH, or cortisol
Potential Side Effects:
- Mild redness at the injection site
- MOTS-C: transient mild nausea (rare)
- AOD-9604: rare headache during the first few days
- No serious adverse events have been reported
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Failed clinical trials — questionable efficacy
The Phase III obesity trial did not meet primary endpoint. Long-term safety as injectable has not been documented (GRAS only for oral use).
📄 Metabolic Pharmaceuticals (Clinical Trial Data)AMPK regulation — effect on glucose metabolism
MOTS-c activates AMPK and modifies glucose metabolism. Combined with antidiabetic drugs, may theoretically cause hypoglycemia. Very few human studies.
📄 Cell Metab 2015References
- AOD9604 lipolytic activity in adipose tissue — Heffernan MA et al., Obesity Research, 2001.
View Source - MOTS-c: a mitochondrial-encoded peptide that acts as an exercise mimetic — Lee C et al., Cell Metab, 2015.
View Source - MOTS-c improves insulin sensitivity and metabolic homeostasis — Reynolds JC et al., Aging Cell, 2021.
View Source
Recommended Supplements
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
GRAS (oral) — Not approved as an injectable
FDA GRAS (oral only)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →